U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939360) titled 'Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction.' on Oct. 23.
Brief Summary: The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020.
Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States.
The expected duration of the study will be six (6) months, and subject participation will take approximately four (4) weeks, including three (4) visits; pretreatment visit, Treatment Day, two (2) week follow-up and four (4) ...